Overcoming Adriamycin Resistance with Verapamil and Norverapamil
Author Information
Author(s): S. Merry, P. Flanigan, E. Schlick, R.I. Freshney, S.B. Kaye
Primary Institution: University of Glasgow
Hypothesis
Can verapamil and its metabolite norverapamil enhance the sensitivity of a murine tumor cell line to adriamycin?
Conclusion
Verapamil and norverapamil can significantly enhance the sensitivity of a murine tumor cell line to adriamycin.
Supporting Evidence
- Verapamil and norverapamil significantly increased the sensitivity of MOG-XMT1 cells to adriamycin.
- The combination of verapamil and norverapamil produced a greater effect on adriamycin sensitivity than either agent alone.
- Statistically significant differences in absorbance were observed in MTT assays with both verapamil and norverapamil.
Takeaway
This study found that two drugs, verapamil and norverapamil, can help make cancer cells more sensitive to a common chemotherapy drug called adriamycin.
Methodology
In vitro cytotoxicity assays were performed using MTT reduction and colony formation as endpoints, with sensitization ratios calculated based on drug concentrations.
Limitations
The pharmacodynamics of drug exposure in vitro may differ from in vivo conditions.
Participant Demographics
Murine tumor cell line derived from a human small cell lung cancer xenograft.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website